
Opinion|Videos|April 22, 2025
Personalizing C3G Treatment: Insights From Experienced Clinicians
Panelists discuss how treatment approaches for C3 glomerulopathy (C3G) have evolved from nonspecific immunosuppression to targeted complement inhibition, with the recent FDA approval of iptacopan marking a significant advancement in disease management.
Advertisement
Video content above is prompted by the following:
C3G Management Discussion
Background Therapy
- All C3G patients require nonimmunosuppressive background therapy:
- Renin-angiotensin-aldosterone system blockers (essential)
- SGLT2 inhibitors (recommended)
- Potential additions: glucagon-like peptide-1 agonists and mineralocorticoid receptor antagonists
Disease Progression
- Most C3G patients will progress despite conservative background therapy
- Management approaches have evolved significantly over the past 15 years
Traditional Immunosuppressive Approaches
- Various nonspecific immunosuppressive regimens have been tried
- Mycophenolate-based regimens with steroids (similar to lupus nephritis treatment) showed the most consistent benefit
- Most effective in patients with nephritic factors (60%-70% chance of significant proteinuria reduction)
- Limitation: Re-biopsies show continued accumulation of chronicity despite treatment
Limitations of B-Cell–Directed Therapies
- Despite C3G having autoimmune characteristics, B-cell–targeting agents have proven ineffective
- Possible explanations:
- Nephritic factors may not always be pathogenic
- Nephritic factors might only initiate the disease process, with complement dysregulation continuing independently afterward
New Era of Complement-Targeting Therapies
- First complement-targeting drug (Iptacopan) received FDA approval for C3G
- At least 1 other similar agent is expected to receive approval soon
- These targeted therapies address the underlying disease mechanism rather than just symptoms
- Even in patients with nephritic factors, complement-targeting therapy is now preferred over antibody-depleting approaches
Clinical Implications
- Treatment paradigm has shifted from nonspecific immunosuppression to targeted complement inhibition
Physicians should consider these newer options as they become available for C3G management
Advertisement
Related to this article

HCPLive previews GOLD 2026 in Philadelphia, November 5-6, with sessions on the 2027 GOLD Report, mucus plugging, and exacerbations, plus expert interviews.

October 2026 allergy news: FDA approvals for berotralstat pellets and remibrutinib, RAPIDe-3 data in HAE, alpha-gal syndrome, and Viaskin Peanut Patch.

Skin clearance and route of administration drove treatment choices among 202 patients with psoriasis in the ENCOMPASS-PP discrete choice experiment.

Alexa Kimball, MD, MPH, reviews tulisokibart safety in hidradenitis suppurativa, its potential in patients with IBD, and what phase 3 trials must answer.

In 20 patients with PAH, lower baseline RVEF was linked to greater RV functional recovery and PVR reduction after 24 weeks of sotatercept, per a CHEST 2026 abstract.

In this segment of her interview, Kimball discusses phase 2b tulisokibart data in hidradenitis suppurativa and the rationale for targeting TL1A.

Oral prifemilast, a PDE4B-selective inhibitor, led to PASI 75 attainment in up to 57.4% of those with psoriasis at week 16 vs 10.8% with placebo.
Advertisement
Advertisement
Trending on HCPLive
1
Oral STAT6 Degrader KT-621 Reduces EASI by 62.6% in Atopic Dermatitis
2
Risankizumab Shows Higher 3-Year Drug Survival in Psoriasis With PsA
3
Q&A: Tulisokibart Results and TL1A Inhibition in HS, With Alexa Kimball, MD, MPH
4
Q&A: Asthma Remission from Year 1 To Year 2 With Depemokimab
5

